ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

Grant

Date/time Interval

  • December 13, 2017 - December 12, 2022

    • Awarded By

    Total Award Amount

  • 54500.00

    • Direct Costs

  • 40073.00

    • Sponsor Award Id

    • Contributor

  • wliang   Investigator  
  • Alva, Elizabeth   Investigator  
  • Aye, Jamie   Investigator  
  • Friedman M.D., Gregory   Principal Investigator  
  • Galtarossa Xavier, Ana   Investigator  
  • Johnston, Emily   Investigator  
  • Kutny M.D., Matthew   Investigator  
  • Metrock, Laura   Investigator  
  • Whelan M.D., Kimberly   Investigator